United Therapeutics Corporation
United Therapeutics Announces Strong Third Quarter 2024 Financial Results
Summary
United Therapeutics Corporation reported robust financial results for the third quarter of 2024, with total revenues growing 23% year-over-year to $748.9 million. The company achieved a 16% increase in net income to $309.1 million, driven by strong sales of its pulmonary products, including Tyvaso, Remodulin, Orenitram, and Unituxin. The earnings per diluted share increased by 19% to $6.39. The company also provided guidance for anticipated clinical data reads and regulatory events that could further drive growth. Additionally, United Therapeutics disclosed an accelerated share repurchase agreement resulting in the repurchase of 3,547,374 shares.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement